MEM 1003

MEM 1003 is a CNS-targeted small molecule drug that acts as a neuronal L-type calcium channel modulator, specifically functioning as an L-type calcium channel blocker. It was developed for the potential treatment of neurological and psychiatric disorders, including Alzheimer's disease and bipolar disorder. The drug was originally developed by Bayer AG and later advanced by Memory Pharmaceuticals Corp., with support from The Stanley Medical Research Institute in some trials. Preclinical studies suggested possible cognitive enhancement and neuroprotective effects due to modulation of calcium homeostasis in neurons. Despite demonstrating good safety and tolerability profiles in early-phase clinical trials, MEM 1003 failed to show efficacy over placebo in pivotal Phase 2a studies for both Alzheimer's disease and acute mania associated with bipolar disorder, leading to discontinuation of its development[1][2][3][7][9].

Other names

MEM 1003MEM1003MEM-1003BAY Z 4406BAY-Z-4406BAY-Z4406BAY-Z 4406